Diabetic Kidney Disease Pipeline

DelveInsight’s Diabetic Kidney Disease pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects in the Diabetic Kidney Disease industry. The disease summary and Diabetic Kidney Disease treatment guidelines are included in a complete description of the Diabetic Kidney Disease pipeline landscape.

Some of the Crucial Findings from the Diabetic Kidney Disease Pipeline Report

• Bayer announced in January 2021 that the US Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) and granted Priority Review for finerenone for the treatment of chronic kidney disease (CKD) and type 2 diabetes patients (T2D).

• Diabetic Kidney Disease pipeline drug which is in phase III clinical trials is Bardoxolone methyl. While DKD pipeline drug in phase II clinical trials is Selonsertib along with others. 

• Some DKD pipeline therapies such as ORBCEL-M, and others are in the phase I/II of DKD clinical trials. 

• Key players in Diabetic Kidney Disease pipeline landscape include Bayer, Reata Pharmaceuticals, Gilead Sciences, Orbsen Therapeutics, Dimerix, CSL Behring, and others. 

To learn more, request sample @ Chronic Kidney Disease Pipeline Landscape

Diabetic Kidney Disease: Overview

Diabetic Kidney Disease (DKD) also known as, Diabetic Nephropathy, is a chronic, progressive disease that develops over time. Diabetic nephropathy is a serious long-term complication that affects about 30% of people with type 1 diabetes (T1D) and 40% of people with type 2 diabetes (T2D). DKD is also linked to a high rate of mortality.

Diabetic Kidney Disease: Symptoms 

Fatigue, anorexia, and swelling of the limbs are common signs of Diabetic Kidney Disease (DKD), which may go unnoticed until the disease is advanced. 

Diabetic Kidney Disease: Treatment

The main goal of treatment is to delay or stop the progression of ESRD. Glycemic and blood pressure control have long been the pillars of treatment, with dietary therapy being a less well-established strategy. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are more efficient in slowing DKD progression.

Diabetic Kidney Disease Pipeline Analysis: Drug Profiles 

Finerenone: Bayer

Product Description

Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA). Finerenone’s marketing authorization application (MAA) for the treatment of chronic kidney disease (CKD) and type 2 diabetes (T2D) has been submitted to the European Medicines Agency (EMA), and the new drug application (NDA) has been accepted by the United States Food and Drug Administration (FDA).

Phase III

NCT02540993: Bayer began a randomised, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study in September 2015 to see if oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes and diabetic kidney disease (FIGARO-DKD).

Get in touch to know more about the Diabetic Kidney Disease Pipeline Therapies

Diabetic Kidney Disease Pipeline Therapies and Key Companies 

• Finerenone: Bayer

• Bardoxolone methyl: Reata Pharmaceuticals

• Selonsertib: Gilead Sciences

• ORBCEL-M: Orbsen Therapeutics

Diabetic Kidney Disease Therapeutics Assessment 

• By Product Type

• Monotherapy

• Combination Therapy

• By Stage

• Discovery

• Pre-Clinical

• Phase I

• Phase II

• Phase III

• Pre-registration

• By Route of Administration

• Inhalation

• Intravenous

• Oral

• Subcutaneous

• By Molecule Type

• Small Molecule

• Stem Cell Therapy

• Gene Therapy

• Targets

• Immune System

• Multiple Kinase

• Protease

• By Mechanism of Action

• Protease Inhibitors

• Immunomodulatory

• Multiple Kinase Inhibitors

Scope of the Report

Coverage: Global

Diabetic Kidney Disease Key Players: Bayer, Reata Pharmaceuticals, Gilead Sciences, Orbsen Therapeutics, Dimerix, CSL Behring, among others

Diabetic Kidney Disease Pipeline Therapies: Finerenone, Bardoxolone methyl, Selonsertib, ORBCEL-M, and others

Table of Contents 

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Key questions answered in the Diabetic Kidney Disease Pipeline Report

• What therapy options are available for Diabetic Kidney Disease?

• How many pharmaceutical companies are working on Diabetic Kidney Disease treatments?

• Which of these companies’ treatments are the most popular?

• What is the total number of Diabetic Kidney Disease medications produced by each company?

• How many Diabetic Kidney Disease pipeline medicines are in early, mid, or late development?

• How many of the therapies in development can be used on their own or in combination with other treatments?

• What are the most significant industry-industry and industry-academy collaborations, mergers and acquisitions, and licencing practises that affect Diabetic Kidney Disease?

Related Reports

Diabetic Cardiomyopathy Pipeline Insights

Get comprehensive analysis of Diabetic Cardiomyopathy pipeline therapies and key companies including Imbria Pharmaceuticals, Applied Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/